This phase II trial studies how well giving interleukin-12 gene and in vivo electroporation-mediated plasmid DNA vaccine therapy works in treating patients with Merkel cell cancer. Placing the gene for interleukin-12 into Merkel cells may help the body build an effective defense to kill tumor cells.

Eligibility Criteria (must meet the following to participate in this
study)

** For Eligibility information, please click on the "Look up trial at NIH" link above. **

Other eligibility criteria may apply.

Research Study Number

7248

Contact

Seattle Cancer Care Alliance Intake Office

Telephone

800-804-8824 / 206-288-1024

KeywordsSkin Cancer; Solid Tumors

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:

Talk to your health care providers first before making decisions about your health care.

Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.